Treatment persistence, lipid lowering, and 3-year clinical outcomes in patients at very high cardiovascular risk on PCSK9 monoclonal antibodies

Parhofer, Klaus G.; Pittrow, David; Birkenfeld, Andreas L.; Fraass, Uwe; Hohenstein, Bernd; Siegert, Carsten; Klotsche, Jens; Steinhagen-Thiessen, Elisabeth; Dexl, Stefan; Schettler, Volker J. J.; Laufs, Ulrich

dc.contributor.author	Birkenfeld, Andreas L.
dc.date.accessioned	2026-10-26T09:16:57Z
dc.date.available	2026-10-26T09:16:57Z
dc.date.issued	2026
dc.identifier.issn	1861-0684
dc.identifier.uri	http://hdl.handle.net/10900/184974
dc.language.iso	en	de_DE
dc.publisher	Berlin : Springer	de_DE
dc.relation.uri	http://dx.doi.org/10.1007/s00392-025-02719-z	de_DE
dc.subject.ddc	610	de_DE
dc.title	Treatment persistence, lipid lowering, and 3-year clinical outcomes in patients at very high cardiovascular risk on PCSK9 monoclonal antibodies	de_DE
dc.type	Article	de_DE
utue.quellen.id	20260422000000_01785
utue.publikation.seiten	288-303	de_DE
utue.personen.roh	Parhofer, Klaus G.
utue.personen.roh	Pittrow, David
utue.personen.roh	Birkenfeld, Andreas L.
utue.personen.roh	Fraass, Uwe
utue.personen.roh	Hohenstein, Bernd
utue.personen.roh	Siegert, Carsten
utue.personen.roh	Klotsche, Jens
utue.personen.roh	Steinhagen-Thiessen, Elisabeth
utue.personen.roh	Dexl, Stefan
utue.personen.roh	Schettler, Volker J. J.
utue.personen.roh	Laufs, Ulrich
dcterms.isPartOf.ZSTitelID	Clinical Research in Cardiology	de_DE
dcterms.isPartOf.ZS-Issue	2	de_DE
dcterms.isPartOf.ZS-Volume	115	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE